136-LB: Health Care Professional (HCP) Perspectives on Support Tools for Diabetes Devices
Authors: MESSER LAUREL H. , VIGERS TIMOTHY B. , AKTURK HALIS K. , FORLENZA GREGORY P. , HUSS KELSEY B. , KARAMI ANGELA J. , MALECHA EMILY , OSER SEAN , POLSKY SARIT , PYLE LAURA , SHAH VIRAL , WADWA R. PAUL , OSER TAMARA 
Published: May 2022

Purpose: To understand the relative importance of support tools for HCPs to increase engagement with diabetes devices
Methods: Primary care, pediatric and adult endocrinology HCPs completed an online survey assessing their comfort with continuous glucose monitors, connected insulin pens, insulin pumps, hybrid closed-loop systems, and their perceived needs for support tools. Hypothetical tools were described and Visual Analog Scales (VAS) (0 to 100) were used to "indicate how useful each tool would be in clinical practice."
Results: 113 primary care HCPs (mean 16.3±10.1 yrs in practice) , 84 adult endocrinology HCPs (10.7±9.2 yrs in practice) , and 34 pediatric endocrinology HCPs (13.6±12.2 yrs in practice) completed the survey. A tool that assists in determining patients' insurance coverage for devices was ranked with the highest median score for all HCP types (VAS score: 90, 99, 95/100 respectively) , followed by an Online Data Platform to access device information (85, 88, 91.5/100) [Figure]. HCPs additionally indicated the importance of device data integration into an electronic health record (EHR) (83, 87.5, 82/100) , support tool accessibility from the EHR (79.5, 71, 75/100) , and device information communication to patients via EHR (78, 73.5, 75/100) .
Conclusion: HCPs from 3 disciplines highlighted the need for clinical tools to work with diabetes devices in clinical practice, with particular interest in insurance aid and data platform.

Disclosure
L. H. Messer: Consultant; Capillary Biomedical, Inc., Dexcom, Inc., Tandem Diabetes Care, Inc., Research Support; Beta Bionics, Inc., Dexcom, Inc., Insulet Corporation, Medtronic. L. Pyle: None. V. Shah: Advisory Panel; Medscape, Sanofi, Consultant; Dexcom, Inc., Research Support; Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Novo Nordisk. R. Wadwa: Advisory Panel; Dompé, Consultant; Beta Bionics, Inc., Other Relationship; Tandem Diabetes Care, Inc., Research Support; Dexcom, Inc., Eli Lilly and Company, Tandem Diabetes Care, Inc. T. Oser: Advisory Panel; Cecelia Health, Dexcom, Inc. T. B. Vigers: None. H. K. Akturk: Research Support; Dexcom, Inc., Eli Lilly and Company, REMD Biotherapeutics. G. P. Forlenza: Advisory Panel; Lilly, Medtronic, Consultant; Dexcom, Inc., Insulet Corporation, Tandem Diabetes Care, Inc., Research Support; Dexcom, Inc., Insulet Corporation, Medtronic, Tandem Diabetes Care, Inc. K. B. Huss: None. A. J. Karami: None. E. Malecha: None. S. Oser: Advisory Panel; Cecelia Health, Children with Diabetes, Inc., Dexcom, Inc., Consultant; American Diabetes Association, Association of Diabetes Care & Education Specialists, Jaeb Center for Health Research, Research Support; American Academy of Family Physicians, Leona M. and Harry B. Helmsley Charitable Trust. S. Polsky: Advisory Panel; Medtronic, Other Relationship; diaTribe, Research Support; Dexcom, Inc., Eli Lilly and Company, Leona M. and Harry B. Helmsley Charitable Trust, Medtronic, National Institute of Diabetes and Digestive and Kidney Diseases, Sanofi-Aventis U. S.

Funding
The Leona M. and Harry B. Helmsley Charitable Trust (G-2206-05306)